TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04047784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Description: An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound (EBUS)
Description: An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn.
Study: NCT03730922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed-immediate reconstruction
Description: Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed reconstruction
Description: Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
Study: NCT02510534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur 150 international units
Description: Menopur 150 international units given x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur 150 international units
Description: Menopur 150 international units given x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin 100 mg
Description: Endometrin 100mg twice daily x 14 days
Study: NCT01941277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Recommendations Exercise Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Exercise Group
Study: NCT01025843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
Study: NCT00664300

Intervention type: BEHAVIORAL
Intervention: Facial expression recognition of emotion
Description: Facial expression recognition test Lexical decision test
Study: NCT01025843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
Study: NCT02296996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Study: NCT04115046

Intervention type: DEVICE
Intervention: ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)
Description: ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.

Intervention type: DEVICE
Intervention: FibroScan
Description: manufactured by Echosens

Intervention type: DEVICE
Intervention: ALOKA ARIETTA 850 -
Description: manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
Study: NCT01041690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03437538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCO-HD
Description: Measurements will be done during a single hemodialysis session with Medium Cut-Off filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCO-HD
Description: Measurements will be done during a single hemodialysis session with Medium Cut-Off filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux HDF
Description: Measurements will be done during a single hemodiafiltration session with standard high-flux filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux HDF
Description: Measurements will be done during a single hemodiafiltration session with standard high-flux filter
Study: NCT00711269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496 (lurasidone HCl)
Description: Lurasidone HCl: 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-13496 (lurasidone HCl)
Description: Lurasidone HCl: 80 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Study: NCT04010786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0247-0829
Description: Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0247-0829)
Description: Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
Study: NCT02915367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminders
Description: Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
Study: NCT03744884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Force efforts with haptic feedback in virtual reality.
Description: A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Force efforts with haptic feedback in virtual reality.
Description: A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
Study: NCT00538980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
Study: NCT00525148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
Study: NCT03020758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried Fruit
Description: Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Carbohydrate Snack
Description: Calorie-matched carbohydrate-rich snack.
Study: NCT01027208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Lyophilized and solvent, IV, 10-50 mg/m²
Study: NCT02783794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
Study: NCT01025843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5478
Description: In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Candesartan cilexetil
Description: Single dose administration of candesartan, 32 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pbo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pbo
Description: Placebo
Study: NCT03069677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
Study: NCT03536494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Review the use of mirabegron and its discontinuation
Description: A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention.
Study: NCT01593072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVI-7537
Description: Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline Solution (NSS)
Description: Normal Saline Solution (NSS)
Study: NCT03936179

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high dose radiation therapy with concurrent chemotherapy
Description: standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
Study: NCT00980889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Steel
Description: ERCP procedure insertion of Metalic Steel Stent, Wallstent®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol
Description: Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
Study: NCT01385826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor alpha monoclonal antibody
Description: The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
Study: NCT04596306

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Intervention: Laparoscopic Cholecystectomy
Description: Laparoscopic Cholecystectomy
Study: NCT03056768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain intervention
Description: 1-year multidomain health promotion (physical, cognitive, nutritional intervention)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Health promotion activities provided by local health bureau.
Study: NCT02108600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
Study: NCT01025843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pbo
Description: Placebo
Study: NCT01300624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verb Network Strengthening Treatment
Description: Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
Study: NCT03450369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB01
Description: Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
Study: NCT01090089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide, Dexamethasone
Description: Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Dexamethasone, PBSCT
Description: Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
Study: NCT01525849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sinus Dilation
Description: Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery
Description: Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
Study: NCT02078882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: abatacept
Description: 125 mg subcutaneously each week for 24 weeks
Study: NCT00306917

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-coated femoral hip stem
Description: total hip replacement
Study: NCT01368614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE Mode of Therapy
Description: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
Study: NCT01025843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pbo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pbo
Description: Placebo
Study: NCT02070757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
Study: NCT02070757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
Study: NCT02253069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Applying Prontosan antiseptic solution to tie-over dressings
Description: Applying a PHMB-based antiseptic to tie-over dressings

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Applying Placebo to tie-over dressings
Description: Placebo control
Study: NCT02598895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04025684

Intervention type: OTHER
Group type: OTHER
Intervention: Oral B Indicator 123
Description: Manual toothbrush (medium bristle stiffness; compact head, UK market).

Intervention type: OTHER
Group type: OTHER
Intervention: Dr Best Original
Description: Manual toothbrush (medium bristle stiffness; regular head, German market)

Intervention type: OTHER
Group type: OTHER
Intervention: Dr Best Multi Expert
Description: Manual toothbrush (medium bristle stiffness; compact head, German market)

Intervention type: OTHER
Group type: OTHER
Intervention: parodontax Interdental
Description: Manual toothbrush (soft bristle stiffness; compact head, German market)
Study: NCT01904422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional periodontal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional periodontal treatment
Study: NCT01705431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On Track
Description: The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
Study: NCT04558333

Intervention type: OTHER
Intervention: blood and exhaled breath specimens
Description: identification of possible biomarkers
Study: NCT04859387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: set of pragmatic shoulder technique
Description: Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
Study: NCT03967886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYD601 20mg
Description: Patients should take drugs an hour before breakfast.
Study: NCT01368614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics OnmiLab BiPAP S mode
Description: Currently cleared Non-Invasive Ventilation (NIV) therapy modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics OmniLab Advanced CPAP mode
Description: Currently cleared NIV therapy modality
Study: NCT03152578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BetaC + Capsaicin Topical Cream
Description: BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.